USA - engelsk - NLM (National Library of Medicine)

depo nf sub, llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg - nucynta (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)] , reserve nucynta tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia nucynta tablets are contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - known or suspected gastrointestinal obstruction, including suspected paralytic ileus [see warnings and precautions (5.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 116.48 mg (equivalent: tapentadol, qty 100 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; lactose monohydrate; iron oxide yellow; purified talc; povidone; titanium dioxide; iron oxide red; polyvinyl alcohol; microcrystalline cellulose; macrogol 3350; iron oxide black - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 87.36 mg (equivalent: tapentadol, qty 75 mg) - tablet, film coated - excipient ingredients: macrogol 3350; polyvinyl alcohol; iron oxide red; croscarmellose sodium; purified talc; lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; magnesium stearate; iron oxide yellow - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tapentadol hydrochloride, quantity: 58.24 mg (equivalent: tapentadol, qty 50 mg) - tablet, film coated - excipient ingredients: purified talc; titanium dioxide; croscarmellose sodium; polyvinyl alcohol; lactose monohydrate; macrogol 3350; microcrystalline cellulose; povidone; magnesium stearate - palexia ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

grunenthal pharma ltd - tapentadol - film-coated tablet - 75 milligram(s) - other opioids; tapentadol

Malta - engelsk - Medicines Authority

grunenthal gmbh zieglerstrasse 6, 52078 aachen, germany - tapentadol - film-coated tablet - tapentadol 75 mg - analgesics

Malta - engelsk - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - film-coated tablet - tapentadol 75 mg - analgesics

USA - engelsk - NLM (National Library of Medicine)

bryant ranch prepack - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 50 mg

USA - engelsk - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - tapentadol 20 mg in 1 ml

USA - engelsk - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - tapentadol hydrochloride (unii: 71204kii53) (tapentadol - unii:h8a007m585) - like other drugs with mu-opioid agonist activity, nucynta® is contraindicated in patients with significant respiratory depression in unmonitored settings or the absence of resuscitative equipment. nucynta® is also contraindicated in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or the absence of resuscitative equipment [see warnings and precautions (5.1)] . like drugs with mu-opioid agonist activity, nucynta® is contraindicated in any patient who has or is suspected of having paralytic ileus. nucynta® is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events [see drug interactions (7.4)] . pregnancy category c. tapentadol hcl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous and subcutaneous exposure during the period of embryofetal organogenesis. w